Tildrakizumab candidates
Tildrakizumab (Ilumya), an Interleukin-23 (IL-23) inhibitor, can provide long-term improvement, even in higher-risk psoriasis patients. Tildrakizumab is a type of drug called a monoclonal antibody. It is a protein that specifically treats certain parts of your immune system. Unlike many other psoriasis treatments, tildrakizumab can be used in higher-risk populations, such as in the elderly or those with psoriasis in addition to other health conditions like inflammatory bowel disease (IBD) or psoriatic arthritis.
